LONDON, UK / ACCESSWIRE / August 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Biogen Inc. (NASDAQ: BIIB ...

IMRALDI has been developed by Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen (NASDAQ, BIIB) and is approved for the treatment of rheumatoid arthritis (RA), juvenile idiopathic ...

Please provide your email address to receive an email when new articles are posted on . The European Medicines Agency has recommended the approval of the Imraldi, making it the third anti-TNF ...